Pfizer (NYSE:Pfe) has agreed to pay nearly $60 million to settle allegations that its Biohaven unit overcharged doctors by promoting prescriptions for the migraine drug Nurtec ODT.

US Department of Justice, Biohaven knowingly subpoenaed the claim